| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 59203.60 | 7402201 |
| Intrinsic value (DCF) | 355090.08 | 44397259 |
| Graham-Dodd Method | n/a | |
| Graham Formula | 1997811.49 | 249788783 |
Aditxt, Inc. (NASDAQ: ADTX) is an innovative biotechnology company focused on immune system health through immune mapping and reprogramming technologies. Headquartered in Richmond, Virginia, Aditxt develops AditxtScore, a proprietary platform enabling individuals to monitor and manage their immune profiles, and Apoptotic DNA Immunotherapy, a nucleic acid-based technology designed to induce immune tolerance. The company is also advancing ADi products targeting organ transplantation, autoimmune diseases, and allergies. With strategic license agreements from Loma Linda University and Stanford University, Aditxt is positioned at the forefront of immune system research. Operating in the high-growth biotechnology sector, Aditxt aims to address critical unmet medical needs in transplantation and autoimmune disorders, leveraging cutting-edge science to improve patient outcomes.
Aditxt presents a high-risk, high-reward investment opportunity in the biotechnology sector. The company's focus on immune system modulation addresses a large and growing market, particularly in autoimmune diseases and organ transplantation. However, with a market cap of just $3.7 million, negative EPS (-$216.59), and significant net losses (-$34.4 million), the company faces substantial financial challenges. Its innovative technologies and university partnerships provide potential upside, but investors should be cautious about its cash position ($833K) relative to operating cash burn (-$16.8 million). Success depends heavily on clinical validation, commercialization of its platforms, and additional funding. The high beta (1.418) indicates significant volatility.
Aditxt operates in the competitive immune therapy and transplantation biotechnology space, competing with both large pharma and specialized biotech firms. Its key differentiator is the AditxtScore immune monitoring platform combined with its Apoptotic DNA Immunotherapy approach, which aims to reprogram immune responses rather than suppress them like many existing therapies. The company's academic collaborations provide access to foundational IP, but it lacks the resources of larger competitors. Aditxt's focus on immune profiling for transplantation could position it well in the growing personalized medicine market, but it faces challenges scaling its technology and demonstrating clinical efficacy. The company's small size allows for agility in research but limits commercialization capabilities. Its technology platform approach gives it potential applications across multiple disease areas, but this diversification comes with added development risk compared to competitors focused on single indications.